Viatris Patent-Cliff Exposure & CMS Drug Spending Portfolio
Viatris (Canonsburg, PA): 112 reconciled FDA prescription therapies (4.6% 2025 to 2030 cliff risk), $1.27B 2024 CMS Part D & Medicaid spend, and 222 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Canonsburg, PA |
| Reconciled FDA Portfolio Therapies | 112 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 4.6% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $1.27B |
| 2024 Medicare Part D Spend | $868.5M |
| 2024 Medicaid Spend | $403.8M |
| California HCAI SB 17 Filings | 222 WAC filings (max 29.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.